Back to School: How biopharma can reboot drug development. Access exclusive analysis here

End points for angiogenesis

The potential benefits of angiogenesis therapy in treating cardiovascular conditions are obvious in theory, but in practice they are proving challenging to demonstrate. This doesn't mean the theory is wrong, but it may mean that companies have to rethink the end points they pick for clinical trials.

Angiogenesis uses growth factors to stimulate blood vessel formation to circumvent blocked vessels.

Read the full 596 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers